A process for preparing 11-deoxyprostaglandin E.sub.1, E.sub.2 and E.sub.3 and analogs thereof is realized by treating an appropriate di(lower)alkyl 3-(optionally substituted)-2-formylcyclopropane-1,1-dicarboxylate with an ylid prepared from a Wittig reagent of formula (AlkO).sub.2 PCCH.sub.2 CO-(c)-CH.sub.3 in which Alk is an alkyl containing one to three carbon atoms and (c) is either (CH.sub.2).sub.q wherein q is an integer from 1 to 6 or cis CH.sub.2 CH=CH(CH.sub.2).sub.r wherein r is an integer from 0 to 3 to obtain the corresponding compound of formula: ##STR1## in which R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl, R.sup.4 is lower alkyl and (c) is as defined herein. The latter compound is reduced with an alkali metal borehydride to yield the corresponding alcohol derivative. Condensation of this alcohol derivative or preferably its corresponding tetrahydropyran-2-yl ether derivative with a triester of formula CH(COOR.sup.6).sub.2 -(a)-(CH.sub.2)pCOOR in which R and R.sup.6 are lower alkyl, (a) is CH.sub.2 CH.sub.2, cis CH=CH or CaC and p is an integer from 2 to 4, gives the corresponding cyclopentanonetriester of formula ##STR2## in which (a), (c), p, R, R.sup.4 and R.sup.6 are as defined herein, R.sup.5 is hydrogen or tetrahydropyran-2-yl, respectively, and R.sup.7 is hydrogen or lower alkyl; the lactonized form of the cyclopentanone-triester being obtained from said alcohol derivative in which R.sup.2 is CH.sub.2 OR.sup.3 wherein R.sup.3 is lower alkanoyl. In the instance when R.sup.5 is tetrahydropyran-2-yl the cyclopentanonetriester is treated with an acid to give the corresponding compound in which R.sup.5 is hydrogen. The instant compound is then treated with a base under aqueous conditions, followed by optional esterification and acylation to give the desired 11-deoxy-prostaglandin derivatives of the formula ##STR3## in which (a), (c) and p, are as defined herein, (b) is trans CH=CH, R is hydrogen or lower alkyl, R.sup.1 is hydrogen or lower alkanoyl and R.sup.2 is hydrogen, lower alkyl or CH.sub.2 OR.sup.3 wherein R.sup.3 is hydrogen or lower alkanoyl. The derivatives possess prostaglandin-like biological activity and methods for their use are given.
本发明提供了一种制备11-去氧
前列腺素E.sub.1、E.sub.2和E.sub.3及其类似物的方法,通过将适当的二(较低)烷基3-(可选取代)-2-甲酰基
环丙烷-1,1-二
羧酸酯与由Wittig试剂制备的ylid反应,该Wittig试剂的
化学式为(AlkO).sub.2
PCCH.sub.2 CO-(c)-CH.sub.3,其中Alk是含有一到三个碳原子的烷基,(c)是(CH.sub.2).sub.q,其中q是1至6的整数,或cis CH.sub.2 CH=CH(CH.sub.2).sub.r,其中r是0至3的整数,以获得相应的化合物,其
化学式为:##STR1## 其中R.sup.2是氢、低烷基或CH.sub.2 OR.sup.3,其中R.sup.3是低烷酰基,R.sup.4是低烷基,(c)如上所定义。后一种化合物与碱
金属
硼氢化物还原,得到相应的醇衍
生物。该醇衍
生物或更好的是其相应的
四氢吡喃-2-基醚衍
生物与
化学式为CH(COOR.sup.6).sub.2-(a)-(CH.sub.2)pCOOR的三酯缩合,其中R和R.sup.6是低烷基,(a)是CH.sub.2 CH.sub.2、cis CH=CH或CaC,p是2至4的整数,得到相应的
环戊酮三酯化合物,其
化学式为:##STR2## 其中(a)、(c)、p、R、R.sup.4和R.sup.6如上所定义,R.sup.5分别为氢或
四氢吡喃-2-基,R.sup.7为氢或低烷基;从所述醇衍
生物中获得
环戊酮三酯的内酯形式,其中R.sup.2为CH.sub.2 OR.sup.3,其中R.sup.3为低烷酰基。当R.sup.5为
四氢吡喃-2-基时,
环戊酮三酯经酸处理,得到相应的化合物,其中R.sup.5为氢。然后在
水性条件下用碱处理该化合物,随后进行可选的酯化和酰化,得到所需的
化学式为:##STR3## 其中(a)、(c)和p如上所定义,(b)为trans CH=CH,R为氢或低烷基,R.sup.1为氢或低烷酰基,R.sup.2为氢、低烷基或CH.sub.2 OR.sup.3,其中R.sup.3为氢或低烷酰基。这些衍
生物具有
前列腺素类似的
生物活性,并提供了其使用方法。